Todos Medical Initiates IRB-Waived Tollovid Market
Post# of 1418
(Total Views: 273)
Posted On: 04/27/2022 10:07:27 AM
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
New York, NY, and Tel Aviv, ISRAEL, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. has received an Institutional Review Board (IRB) waiver to initiate a market research study to gather and evaluate consumer feedback regarding the use of the Company’s 3CL protease inhibitor immune support dietary supplement products Tollovid® and Tollovid Daily™ in their COVID and Long COVID (aka Post-Acute Sequalae of SARS-CoV-2, or “PASC”) journeys. The objective of the study will be to determine whether there is sufficient real-world evidence to support a potential product development program for Tollovid and/or Tollovid Daily in the treatment of Acute COVID and/or Long COVID. Tollovid and Tollovid Daily are not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID. In the weeks ahead, the Company will be contacting customers electronically to complete surveys prepared by our team of physician-scientists to help guide our next steps.
Concurrent with this announcement, the Company announced that it will be offering a 50% discount on the price of Tollovid Maximum Strength through close of business on May 31st, 2022.
Amazon – Tollovid® Maximum Strength
www.MyTollovid.com
“In the last year we have heard anecdotal reports from customers who have experienced great success using our dietary supplements,” said Gerald E. Commissiong, President and CEO of Todos Medical. “These reports eventually piqued the curiosity of physicians who successfully used our products to help patients, with two such successful Long COVID case studies having been made public and several others in various stages of completion. Based on these, we are preparing for an observational study for Tollovid in Long COVID, and have received overwhelming interest from physicians and patients in participating. This surprising level of interest was the impetus behind accelerating our data gathering efforts by starting the assessment of Tollovid and Tollovid Daily in our existing customer base to determine whether the reviews and anecdotal reports we have heard from clients are in fact part of a more significant pattern of activity that could be codified using Good Clinical Practice (GCP) standards so that the data could be shared with regulators.”
Mr. Commissiong continued, “Listening to customers is a core business principal, which allowed us to realize that we were attracting many solution-seekers willing to try our products if we improved the affordability to help them overcome that barrier. In the short run this could affect our profit margins which are currently being used to re-invest in research & development for botanical drug Tollovir® in the treatment of hospitalized COVID-19, and Videssa® for the early detection of breast cancer. However, we felt it was more important to immediately increase access to the Tollovid Maximum Strength product. Our strategy is to increase total profit through additional sales volume, and our marketing team recently linked an uptick in sales to the Long COVID physician case studies, including international interest. If successful, aspects of these temporary moves could become permanent and allow us to accelerate investment into critical research so that we can drive these important products to market faster, because what we will lose in per bottle profit will be more than gained in overall sales volume. As a research driven company, we take great care to carefully quality control our products. We look forward to engaging with our customers in the weeks ahead to gather key data that could further drive our push to bring forward solutions for customers and patients.”
https://investor.todosmedical.com/news-events...t-research
New York, NY, and Tel Aviv, ISRAEL, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. has received an Institutional Review Board (IRB) waiver to initiate a market research study to gather and evaluate consumer feedback regarding the use of the Company’s 3CL protease inhibitor immune support dietary supplement products Tollovid® and Tollovid Daily™ in their COVID and Long COVID (aka Post-Acute Sequalae of SARS-CoV-2, or “PASC”) journeys. The objective of the study will be to determine whether there is sufficient real-world evidence to support a potential product development program for Tollovid and/or Tollovid Daily in the treatment of Acute COVID and/or Long COVID. Tollovid and Tollovid Daily are not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID. In the weeks ahead, the Company will be contacting customers electronically to complete surveys prepared by our team of physician-scientists to help guide our next steps.
Concurrent with this announcement, the Company announced that it will be offering a 50% discount on the price of Tollovid Maximum Strength through close of business on May 31st, 2022.
Amazon – Tollovid® Maximum Strength
www.MyTollovid.com
“In the last year we have heard anecdotal reports from customers who have experienced great success using our dietary supplements,” said Gerald E. Commissiong, President and CEO of Todos Medical. “These reports eventually piqued the curiosity of physicians who successfully used our products to help patients, with two such successful Long COVID case studies having been made public and several others in various stages of completion. Based on these, we are preparing for an observational study for Tollovid in Long COVID, and have received overwhelming interest from physicians and patients in participating. This surprising level of interest was the impetus behind accelerating our data gathering efforts by starting the assessment of Tollovid and Tollovid Daily in our existing customer base to determine whether the reviews and anecdotal reports we have heard from clients are in fact part of a more significant pattern of activity that could be codified using Good Clinical Practice (GCP) standards so that the data could be shared with regulators.”
Mr. Commissiong continued, “Listening to customers is a core business principal, which allowed us to realize that we were attracting many solution-seekers willing to try our products if we improved the affordability to help them overcome that barrier. In the short run this could affect our profit margins which are currently being used to re-invest in research & development for botanical drug Tollovir® in the treatment of hospitalized COVID-19, and Videssa® for the early detection of breast cancer. However, we felt it was more important to immediately increase access to the Tollovid Maximum Strength product. Our strategy is to increase total profit through additional sales volume, and our marketing team recently linked an uptick in sales to the Long COVID physician case studies, including international interest. If successful, aspects of these temporary moves could become permanent and allow us to accelerate investment into critical research so that we can drive these important products to market faster, because what we will lose in per bottle profit will be more than gained in overall sales volume. As a research driven company, we take great care to carefully quality control our products. We look forward to engaging with our customers in the weeks ahead to gather key data that could further drive our push to bring forward solutions for customers and patients.”
https://investor.todosmedical.com/news-events...t-research
(1)
(0)